Halogen-substituted trimetoquinol analogs as thromboxane A2 receptor antagonists in platelets and aorta

Karl J. Romstedt, Yangmee Shin, Gamal Shams, Kathrine Doyle, Vimon Tantishaiyakul, Michael T. Clark, Adeboye Adejare, Akihiko Hamada, Duane Miller, Dennis R. Feller

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Trimetoquinol (TMQ) is a non-prostanoid compound that blocks prostaglandin H2/ thromboxane A2 (TXA2) receptor-mediated responses initiated by a prostaglandin (PG) H2 analog, U46619, in human platelets and rat aorta. Ring flourine-substituted TMQ analogs selectively antagonized PG-dependent human platelet activation induced by U46619, arachidonic acid, collagen, ADP or epinephrine; and were about 300-fold less potent as inhibitors of PG-independent responses mediated by thrombin or bacterial phospholipase C. For each inducer of the PG-dependent pathway, the rank order of inhibitory potency was identical (TMQ > 8-fluoro-TMQ > 5-fluoro-TMQ). Iodine substitution yielded a similar rank order of antagonism against U46619-induced platelet activation (TNQ > 8-iodo- TMQ > 5-iodo-TMQ), and all TMQ analogs inhibited platelet aggregation in whole bloods as well as in platelet-rich plasma. Inhibition of specific [3H]SQ 29,548 binding by TMQ analogs was highly correlated with inhibition of functional responses to U46619. Radioligand binding experiments using TMQ analogs with rat platelets showed no interspecies differece in comparison with human platelets. The rank order of inhibitorypotencies for the fluorinated (but not iodinated) TMQ analogs changed in rat thoracic aorta with 8-fluoro-TMQ > TMQ ≥ 5-fluoro-TMQ as antagonists of U46619-induced vascular contraction. These findings demonstrate that the primary mechanism of antiplatelet action of TMQ analogs is related to a blockade of TXA2 receptor sites, and ring-halogenated TMQ analogs distinguish between TXA2-mediated functional responses in vascular smooth muscle and platelets.

Original languageEnglish (US)
Pages (from-to)2051-2059
Number of pages9
JournalBiochemical Pharmacology
Volume46
Issue number11
DOIs
StatePublished - Dec 3 1993

Fingerprint

Tretoquinol
Prostaglandin H2 Receptors Thromboxane A2
Halogens
Platelet Aggregation Inhibitors
Platelets
Aorta
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Blood Platelets
Rats
Platelet Activation
Prostaglandins
Chemical activation
Prostaglandin H2

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Pharmacology

Cite this

Romstedt, K. J., Shin, Y., Shams, G., Doyle, K., Tantishaiyakul, V., Clark, M. T., ... Feller, D. R. (1993). Halogen-substituted trimetoquinol analogs as thromboxane A2 receptor antagonists in platelets and aorta. Biochemical Pharmacology, 46(11), 2051-2059. https://doi.org/10.1016/0006-2952(93)90647-F

Halogen-substituted trimetoquinol analogs as thromboxane A2 receptor antagonists in platelets and aorta. / Romstedt, Karl J.; Shin, Yangmee; Shams, Gamal; Doyle, Kathrine; Tantishaiyakul, Vimon; Clark, Michael T.; Adejare, Adeboye; Hamada, Akihiko; Miller, Duane; Feller, Dennis R.

In: Biochemical Pharmacology, Vol. 46, No. 11, 03.12.1993, p. 2051-2059.

Research output: Contribution to journalArticle

Romstedt, KJ, Shin, Y, Shams, G, Doyle, K, Tantishaiyakul, V, Clark, MT, Adejare, A, Hamada, A, Miller, D & Feller, DR 1993, 'Halogen-substituted trimetoquinol analogs as thromboxane A2 receptor antagonists in platelets and aorta', Biochemical Pharmacology, vol. 46, no. 11, pp. 2051-2059. https://doi.org/10.1016/0006-2952(93)90647-F
Romstedt, Karl J. ; Shin, Yangmee ; Shams, Gamal ; Doyle, Kathrine ; Tantishaiyakul, Vimon ; Clark, Michael T. ; Adejare, Adeboye ; Hamada, Akihiko ; Miller, Duane ; Feller, Dennis R. / Halogen-substituted trimetoquinol analogs as thromboxane A2 receptor antagonists in platelets and aorta. In: Biochemical Pharmacology. 1993 ; Vol. 46, No. 11. pp. 2051-2059.
@article{8dd4d0cfbb7848e1bbe8ba71fa2345fc,
title = "Halogen-substituted trimetoquinol analogs as thromboxane A2 receptor antagonists in platelets and aorta",
abstract = "Trimetoquinol (TMQ) is a non-prostanoid compound that blocks prostaglandin H2/ thromboxane A2 (TXA2) receptor-mediated responses initiated by a prostaglandin (PG) H2 analog, U46619, in human platelets and rat aorta. Ring flourine-substituted TMQ analogs selectively antagonized PG-dependent human platelet activation induced by U46619, arachidonic acid, collagen, ADP or epinephrine; and were about 300-fold less potent as inhibitors of PG-independent responses mediated by thrombin or bacterial phospholipase C. For each inducer of the PG-dependent pathway, the rank order of inhibitory potency was identical (TMQ > 8-fluoro-TMQ > 5-fluoro-TMQ). Iodine substitution yielded a similar rank order of antagonism against U46619-induced platelet activation (TNQ > 8-iodo- TMQ > 5-iodo-TMQ), and all TMQ analogs inhibited platelet aggregation in whole bloods as well as in platelet-rich plasma. Inhibition of specific [3H]SQ 29,548 binding by TMQ analogs was highly correlated with inhibition of functional responses to U46619. Radioligand binding experiments using TMQ analogs with rat platelets showed no interspecies differece in comparison with human platelets. The rank order of inhibitorypotencies for the fluorinated (but not iodinated) TMQ analogs changed in rat thoracic aorta with 8-fluoro-TMQ > TMQ ≥ 5-fluoro-TMQ as antagonists of U46619-induced vascular contraction. These findings demonstrate that the primary mechanism of antiplatelet action of TMQ analogs is related to a blockade of TXA2 receptor sites, and ring-halogenated TMQ analogs distinguish between TXA2-mediated functional responses in vascular smooth muscle and platelets.",
author = "Romstedt, {Karl J.} and Yangmee Shin and Gamal Shams and Kathrine Doyle and Vimon Tantishaiyakul and Clark, {Michael T.} and Adeboye Adejare and Akihiko Hamada and Duane Miller and Feller, {Dennis R.}",
year = "1993",
month = "12",
day = "3",
doi = "10.1016/0006-2952(93)90647-F",
language = "English (US)",
volume = "46",
pages = "2051--2059",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Halogen-substituted trimetoquinol analogs as thromboxane A2 receptor antagonists in platelets and aorta

AU - Romstedt, Karl J.

AU - Shin, Yangmee

AU - Shams, Gamal

AU - Doyle, Kathrine

AU - Tantishaiyakul, Vimon

AU - Clark, Michael T.

AU - Adejare, Adeboye

AU - Hamada, Akihiko

AU - Miller, Duane

AU - Feller, Dennis R.

PY - 1993/12/3

Y1 - 1993/12/3

N2 - Trimetoquinol (TMQ) is a non-prostanoid compound that blocks prostaglandin H2/ thromboxane A2 (TXA2) receptor-mediated responses initiated by a prostaglandin (PG) H2 analog, U46619, in human platelets and rat aorta. Ring flourine-substituted TMQ analogs selectively antagonized PG-dependent human platelet activation induced by U46619, arachidonic acid, collagen, ADP or epinephrine; and were about 300-fold less potent as inhibitors of PG-independent responses mediated by thrombin or bacterial phospholipase C. For each inducer of the PG-dependent pathway, the rank order of inhibitory potency was identical (TMQ > 8-fluoro-TMQ > 5-fluoro-TMQ). Iodine substitution yielded a similar rank order of antagonism against U46619-induced platelet activation (TNQ > 8-iodo- TMQ > 5-iodo-TMQ), and all TMQ analogs inhibited platelet aggregation in whole bloods as well as in platelet-rich plasma. Inhibition of specific [3H]SQ 29,548 binding by TMQ analogs was highly correlated with inhibition of functional responses to U46619. Radioligand binding experiments using TMQ analogs with rat platelets showed no interspecies differece in comparison with human platelets. The rank order of inhibitorypotencies for the fluorinated (but not iodinated) TMQ analogs changed in rat thoracic aorta with 8-fluoro-TMQ > TMQ ≥ 5-fluoro-TMQ as antagonists of U46619-induced vascular contraction. These findings demonstrate that the primary mechanism of antiplatelet action of TMQ analogs is related to a blockade of TXA2 receptor sites, and ring-halogenated TMQ analogs distinguish between TXA2-mediated functional responses in vascular smooth muscle and platelets.

AB - Trimetoquinol (TMQ) is a non-prostanoid compound that blocks prostaglandin H2/ thromboxane A2 (TXA2) receptor-mediated responses initiated by a prostaglandin (PG) H2 analog, U46619, in human platelets and rat aorta. Ring flourine-substituted TMQ analogs selectively antagonized PG-dependent human platelet activation induced by U46619, arachidonic acid, collagen, ADP or epinephrine; and were about 300-fold less potent as inhibitors of PG-independent responses mediated by thrombin or bacterial phospholipase C. For each inducer of the PG-dependent pathway, the rank order of inhibitory potency was identical (TMQ > 8-fluoro-TMQ > 5-fluoro-TMQ). Iodine substitution yielded a similar rank order of antagonism against U46619-induced platelet activation (TNQ > 8-iodo- TMQ > 5-iodo-TMQ), and all TMQ analogs inhibited platelet aggregation in whole bloods as well as in platelet-rich plasma. Inhibition of specific [3H]SQ 29,548 binding by TMQ analogs was highly correlated with inhibition of functional responses to U46619. Radioligand binding experiments using TMQ analogs with rat platelets showed no interspecies differece in comparison with human platelets. The rank order of inhibitorypotencies for the fluorinated (but not iodinated) TMQ analogs changed in rat thoracic aorta with 8-fluoro-TMQ > TMQ ≥ 5-fluoro-TMQ as antagonists of U46619-induced vascular contraction. These findings demonstrate that the primary mechanism of antiplatelet action of TMQ analogs is related to a blockade of TXA2 receptor sites, and ring-halogenated TMQ analogs distinguish between TXA2-mediated functional responses in vascular smooth muscle and platelets.

UR - http://www.scopus.com/inward/record.url?scp=0027370911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027370911&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(93)90647-F

DO - 10.1016/0006-2952(93)90647-F

M3 - Article

VL - 46

SP - 2051

EP - 2059

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 11

ER -